Extension Study to Evaluate the Long-Term Safety and Tolerability of MBX 2109 in Patients With Hypoparathyroidism
Trial details
- Registry ID
- NCT06531941
- Drugs studied
- 200-1600 µg of MBX 2109 once-weekly by subcutaneous injection, 400 µg of MBX 2109 once-weekly by subcutaneous injection